Wedmont Private Capital’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.15M Buy
8,666
+231
+3% +$79.1K 0.09% 131
2026
Q1
$2.95M Sell
8,435
-106
-1% -$37.8K 0.1% 125
2025
Q4
$2.92M Buy
8,541
+591
+7% +$187K 0.1% 122
2025
Q3
$2.35M Sell
7,950
-316
-4% -$91.6K 0.09% 134
2025
Q2
$2.45M Buy
8,266
+721
+10% +$204K 0.1% 119
2025
Q1
$2.16M Buy
7,545
+731
+11% +$216K 0.11% 109
2024
Q4
$1.79M Buy
6,814
+1,395
+26% +$414K 0.09% 131
2024
Q3
$1.72M Buy
5,419
+255
+5% +$83.4K 0.1% 123
2024
Q2
$1.71M Buy
5,164
+632
+14% +$186K 0.11% 113
2024
Q1
$1.23M Buy
4,532
+29
+0.6% +$8.49K 0.09% 147
2023
Q4
$1.4M Buy
4,503
+859
+24% +$234K 0.11% 113
2023
Q3
$990K Buy
3,644
+788
+28% +$197K 0.1% 129
2023
Q2
$650K Sell
2,856
-457
-14% -$106K 0.07% 191
2023
Q1
$831K Sell
3,313
-389
-11% -$95.5K 0.11% 133
2022
Q4
$1.02M Buy
3,702
+605
+20% +$162K 0.15% 100
2022
Q3
$698K Sell
3,097
-51
-2% -$12.4K 0.14% 118
2022
Q2
$766K Buy
3,148
+395
+14% +$96.8K 0.17% 92
2022
Q1
$674K Buy
2,753
+717
+35% +$165K 0.15% 111
2021
Q4
$470K Buy
+2,036
New +$430K 0.14% 115

Other funds holding AMGN

Wedmont Private Capital's AMGN Position: Q2 2026 in Review

Wedmont Private Capital increased its Amgen (AMGN) stake by 2.7% in Q2 2026, buying an estimated $79.1K and bringing the position to 8,666 shares worth $3.15M. The position accounts for 0.09% of the portfolio, ranked #131.

Wedmont Private Capital first reported a position in AMGN in Q4 2021 and has held it in 19 quarters since. 1,059 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Wedmont Private Capital held 8,666 shares of Amgen worth $3.15M as of Q2 2026.
  • Wedmont Private Capital bought 231 Amgen shares in Q2 2026, an estimated $79.1K.
  • Amgen made up 0.09% of Wedmont Private Capital's portfolio in Q2 2026, its #131 holding.
  • Wedmont Private Capital first reported a position in Amgen in Q4 2021 and has held it in 19 quarters since.
  • 1,059 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Wedmont Private Capital's 13F filing for Q2 2026, filed 13 Jul 2026.